Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 25

ALNYLAM PHARMACEUTICALS, INC.

Form 25 July 27, 2015

### **UNITED STATES**

### SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

#### **FORM 25**

### NOTIFICATION OF REMOVAL FROM LISTING AND/OR

### **REGISTRATION UNDER SECTION 12(b) OF THE**

### **SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number: <u>001-36407</u>

Issuer: Alnylam Pharmaceuticals, Inc.

**Exchange: NASDAQ Stock Market LLC** 

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

## 300 Third Street

### Cambridge, MA 02142

### (617) 551-8200

(Address, including zip code, and telephone number, including area code, of Issuer s principal executive offices)

### Preferred Stock Purchase Rights

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

- " 17 CFR 240.12d2-2(a)(1)
- " 17 CFR 240.12d2-2(a)(2)
- " 17 CFR 240.12d2-2(a)(3)

# Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 25

- " 17 CFR 240.12d2-2(a)(4)
- " Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.<sup>1</sup>
- Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Alnylam Pharmaceuticals, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

July 27, 2015By: /s/ Michael P. MasonVice President, Finance and<br/>TreasurerDateNameTitle

Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.